Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page




    Olfactory dysfunction quantified by olfactometry in patients with SARS-Cov-2 infection MESHD

    Authors: Maria Teresa Cervilla; Irene Gutierrez; Maria Romero; Javier Garcia-Gomez

    doi:10.21203/rs.3.rs-35796/v1 Date: 2020-06-15 Source: ResearchSquare

    Objective: To quantify olfactory dysfunction by olfactometry in patients with laboratory confirmed SARS-Cov-2 infection MESHD.Methods: Patients from a particular Spanish health area with SARS-Cov-2 infection MESHD were recruited to study the loss of smell. Olfactometry was performed using the Sniffin Sticks test. The following clinical symtoms were studied: ENT symptoms related to infection MESHD, duration of sensorineural loss, subjective and objective score of loss of smell, and its temporal relationship with other systemic symptoms.Results: A total of 51 patients with SARS-Cov-2 infection MESHD completed the study. A total of 86.3% reported subjective loss of smell capacity. Objective loss of olfactory ability was quantified by olfactometry in 22% of patients. Statistical significance was demonstrated between the group of patients with anosmia HP/ hyposmia HP and the Sniffin Sticks test (p-value: 0.013). The most frequent ENT symptoms in patients with quantified olfactory loss consisted of nasal obstruction MESHD nasal obstruction HP, absence of rhinorrhea HP, sore throat, and ear pain HP pain MESHD. The subjective olfactory recovery rate prior to performing olfactometry was 64.3% of the sample. A total of 77% of patients in whom olfactory loss was quantified by olfactometry reported a subjective duration of more than 15 days.Conclusion: Olfactory dysfunction is an objective clinical finding in patients with SARS- Cov-2 infection MESHD. Its persistence has been demonstrated beyond the first month after infection MESHD. Their quantitative study should be continued to determine the recovery rate and its possible long-term sequelae, as well as treatments to improve the quality of life of these patients.

    Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

    Authors: Annemarie B Docherty; Ewen M Harrison; Christopher A Green; Hayley E Hardwick; Riinu Pius; Lisa Norman; Karl A Holden; Jonathan M Read; Frank Dondelinger; Gail Carson; Laura Merson; James Lee; Daniel Plotkin; Louise Sigfrid; Sophie Halpin; Clare Jackson; Carrol Gamble; Peter W Horby; Jonathan S Nguyen-Van-Tam; Jake Dunning; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple

    doi:10.1101/2020.04.23.20076042 Date: 2020-04-28 Source: medRxiv

    Objective: To characterize the clinical features of patients with severe COVID-19 in the UK. Design: Prospective observational cohort study with rapid data gathering and near real-time analysis, using a pre-approved questionnaire adopted by the WHO. Setting: 166 UK hospitals between 6th February and 18th April 2020. Participants: 16,749 people with COVID-19. Interventions: No interventions were performed, but with consent samples were taken for research purposes. Many participants were co-enrolled in other interventional studies and clinical trials. Results: The median age TRANS was 72 years [IQR 57, 82; range 0, 104], the median duration of symptoms before admission was 4 days [IQR 1,8] and the median duration of hospital stay was 7 days [IQR 4,12]. The commonest comorbidities were chronic cardiac disease MESHD (29%), uncomplicated diabetes (19%), non-asthmatic chronic pulmonary disease MESHD (19%) and asthma MESHD asthma HP (14%); 47% had no documented reported comorbidity. Increased age TRANS and comorbidities including obesity MESHD obesity HP were associated with a higher probability of mortality. Distinct clusters of symptoms were found: 1. respiratory ( cough MESHD cough HP, sputum, sore throat, runny nose, ear pain HP pain MESHD, wheeze HP, and chest pain MESHD chest pain HP); 2. systemic ( myalgia MESHD myalgia HP, joint pain MESHD pain HP and fatigue MESHD fatigue HP); 3. enteric ( abdominal pain MESHD abdominal pain HP, vomiting MESHD vomiting HP and diarrhoea). Overall, 49% of patients were discharged alive, 33% have died and 17% continued to receive care at date of reporting. 17% required admission to High Dependency or Intensive Care Units; of these, 31% were discharged alive, 45% died and 24% continued to receive care at the reporting date. Of those receiving mechanical ventilation, 20% were discharged alive, 53% died and 27% remained in hospital. Conclusions: We present the largest detailed description of COVID-19 in Europe, demonstrating the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks. Trial documentation: Available at https://isaric4c.net/protocols . Ethical approval in England and Wales (13/SC/0149), and Scotland (20/SS/0028). ISRCTN (pending).

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.